Newsroom
Latest News
- Business15 February 2018
Kick-off meeting in Costa Rica
- Business02 November 2017
Alvogen first to market with generic equivalent to Tamiflu® powder for oral suspension
- Business30 October 2017
The Race goes on
- Business30 October 2017
Alvogen Day around the world
- Business05 October 2017
Alvogen obtains first approval for glatiramer acetate 40 mg/mL in Europe
- Business19 September 2017
Alvogen wins international branding awards
- Business18 September 2017
Alvogen’s senior management team gathers in Iceland for annual Kick-off meeting
- Business11 September 2017
Alvogen subsidiary confirms ANDA filing and patent challenge for generic Revlimid®
- Business06 September 2017
Alvogen adds Qsymia to its anti-obesity portfolio in Korea
- Business15 August 2017
Alvogen announces acquisition to expand Russian business
- Business16 June 2017
And the winner is … Alvogen again!
- Business08 February 2017
Are you our next partner?
- Business06 February 2017
Global kick-off in Malta
- Business12 December 2016
Alvogen launches the first generic equivalent to Tamiflu® capsules in the United States
- Business01 December 2016
Alvogen acquires leading nasal spray device in Russia
- Business14 October 2016
Alvogen scores in Barcelona
- Business05 September 2016
Alvogen launches first generic equivalent of Copaxone(TM) in Europe
- Business18 August 2016
Alvogen warming up for CPhI 2016 in Barcelona
- Charity13 June 2016
Color Run more colorful than ever!
- Business08 June 2016
Alvotech opens state-of-the-art biosimilar facility in Iceland
- Business04 May 2016
Alvogen launches first generic equivalent of zoladex
